Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02084446
Recruitment Status : Completed
First Posted : March 12, 2014
Last Update Posted : February 22, 2019
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Ronaldo de Matos Esmeraldo, MD, Hospital Geral de Fortaleza

Tracking Information
First Submitted Date  ICMJE December 7, 2012
First Posted Date  ICMJE March 12, 2014
Last Update Posted Date February 22, 2019
Study Start Date  ICMJE December 2012
Actual Primary Completion Date July 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 7, 2014)
Incidence of cytomegalovirus (CMV) infection (viremia) or disease (syndrome or invasive disease) during the first year of transplantation [ Time Frame: Month 12 ]
Blood (for CMV detection) samples will be evaluated by PCR for the detection of viral infections
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 7, 2014)
  • Composite efficacy failure rates demonstrated by treated biopsy proven acute rejection episodes (BPAR), graft loss, death, loss to follow-up at months 6 and 12 [ Time Frame: Weeks 1 and 2, Months 1, 2, 3, 6 and 12 ]
    Acute Rejection Treated acute rejection is defined as a clinically suspected acute rejection, biopsy-proven or not, who was treated and confirmed by the investigator according to treatment response. Treated biopsy proven acute rejection BPAR is defined as a clinically suspected acute rejection confirmed by biopsy. A biopsy proven acute rejection is defined as a biopsy classified as grade IA, IB, IIA, IIB, or III. Graft Loss The graft loss is considered from the day when the patient begins dialysis and is not possible to remove he/she from subsequent dialysis. If the patient undergoes a graft nephrectomy, then the day of nephrectomy is the day of graft loss.
  • • Graft function measured as calculated creatinine clearance according to the Cockcroft and Gault formula at 6 and 12 months after transplantation [ Time Frame: Weeks 1 and 2, and Months 1, 2, 3, 6 and 12 ]
    Graft function will be evaluated by serum creatinine and creatinine clearance calculated by Cockcroft & Gault formula. Quantitative proteinuria will also be evaluated.
  • Incidence of proteinuria [ Time Frame: Day 28 and months 3, 6, 9, and 12 after transplantation ]
    Proteinuria will be evaluated in urine samples.
  • Safety Secondary Objectives - incidence of bone marrow suppression, gastrointestinal events, BKV infection, new onset diabetes mellitus; malignancies, dyslipidemia. [ Time Frame: Week 2 and Months 1, 2, 3, 6 and 12 ]
    Bone marrow suppression will be evaluated by blood cells count. Gastrointestinal events will be evaluated by patient symptoms report and investigator evaluation. Blood samples will be evaluated by PCR for the detection of BKV infections. Incidence of new onset diabetes mellitus (NODM) will be assessed by the occurrence of patients who are receiving glucose lowering treatment for more than 30 days post-transplant or with a randomized fasting plasma glucose level ≥ 200 mg/dL with two FPG levels ≥ 126 mg/dL or with a 2 hours plasma glucose OGTT ≥ 200 mg/dL post-transplant. Malignancies will be assessed by investigator during patient visits. Dyslipidemia will be assessed by cholesterol levels > 350 mg/dL or triglycerides levels > 500 mg/dL.
  • Incidence of cytomegalovirus (CMV) infection (viremia) or disease (syndrome or invasive disease) during the first year of transplantation [ Time Frame: Week 2, Months 1, 2, 3 and 6 ]
    Blood (for CMV detection) samples will be evaluated by PCR for the detection of viral infections
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
Official Title  ICMJE Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study
Brief Summary

This is a 12-month single center, randomized, open-label, single center study designed to compare the safety and efficacy of everolimus and very low dose tacrolimus versus enteric-coated sodium mycophenolate and low tacrolimus exposure in de novo kidney transplant recipients.

The purpose of this study is to compare safety and efficacy of two immunosuppressive regimens based on low tacrolimus exposure combined to everolimus or to enteric-coated mycophenolate sodium (EC-MPS) in de novo kidney transplant recipients.

Detailed Description

The study will consist of two periods: an initial period of 3 months during which all patients in both groups will be monitored in accordance with the same variation of C-0h tacrolimus and a second study period of 9 months (from month 4 to month 12) in which patients will be monitored according to two different targets of C-0h tacrolimus.

At the screening visit and before any assessment related to the study, patients must give their informed consent in writing.

All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice.

The evaluations of baseline visit occur within 24 hours after transplantation and prior to the first dose of study drug.

Randomization will be performed within 24 hours after transplantation and after the baseline visit assessments. Patients will be randomized in a 1:1 ratio to one of two groups (everolimus with very low dose of tacrolimus versus sodium mycophenolate with low dose of tacrolimus).

Approximately 120 patients who meet the inclusion criteria will receive their first dose everolimus (initial dose of 1 mg twice a day) or sodium mycophenolate (initial dose of 720 mg twice a day) not more than 24 hours after transplantation. Everolimus trough blood levels will be measured at pre-specified timepoints in order to ensure that trough levels are above 3 ng/ml and below 8 ng/ml for the duration of the study.

Tacrolimus will be started within 48 hours after graft reperfusion at an initial dose of 0.1 mg/kg/day. The dose of tacrolimus will be adjusted to target the C-0h value within the pre-established desired range.

In the everolimus group with very low dose of tacrolimus, tacrolimus dose should be reduced at the end of months three after transplantation. Patients with either acute rejection grade ≥ Banff IIB or more than one treated acute rejection since entering the study and patients with either acute rejection during the third month will not have the dose of tacrolimus reduced; however, they will be encouraged to remain in the study. These patients will be excluded from the per protocol population analysis, but will be analyzed in the Intention To Treat population.

If patients present delayed graft function (DGF), the start of tacrolimus can be postponed for up to and including 7 days.

During the 12 months treatment period, patient visits will occur at the selection visit, baseline visit, at 1, 2, 4 and 8 weeks and at 3, 6 and 12 months. Day 1 is the day of the first administration of everolimus or sodium mycophenolate.

Population: Study population will consist of a group of male or female transplant recipients 18-75 years of age undergoing primary renal transplantation and who received an organ from a living or deceased donor.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE
  • Transplantation Infection
  • Cytomegalovirus Infections
Intervention  ICMJE
  • Drug: Everolimus
    Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
    Other Name: Certican, Zortress
  • Drug: Very Low Tacrolimus
    Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
    Other Name: Very low Prograf
  • Drug: Low Tacrolimus
    Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
    Other Name: Low Prograf
  • Drug: Steroids
    Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
    Other Names:
    • Prednisone
    • Methylprednisolone
  • Drug: Thymoglobulin
    All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).
    Other Names:
    • ATG
    • rabbit Thymoglobulin (r-ATG)
  • Drug: Sodium Mycophenolate
    Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
    Other Name: Myfortic
Study Arms  ICMJE
  • Active Comparator: Mycophenolate + Low Tacrolimus

    Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1. Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.

    Steroids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.

    Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg).

    Interventions:
    • Drug: Low Tacrolimus
    • Drug: Steroids
    • Drug: Thymoglobulin
    • Drug: Sodium Mycophenolate
  • Experimental: Everolimus + Very Low Tacrolimus

    Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.

    Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.

    Corticoids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.

    Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg).

    Interventions:
    • Drug: Everolimus
    • Drug: Very Low Tacrolimus
    • Drug: Steroids
    • Drug: Thymoglobulin
Publications * de Sandes-Freitas TV, Pinheiro PMA, Sales MLMBO, Girão CM, Campos ÉF, Esmeraldo RM. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial. Transpl Int. 2018 Dec;31(12):1345-1356. doi: 10.1111/tri.13313. Epub 2018 Jul 31.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 7, 2014)
120
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 2017
Actual Primary Completion Date July 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female renal recipients 18-75 years of age undergoing kidney transplantation, from a primary deceased donor (including expanded criteria donor organs), living unrelated or non-HLA identical living related donor kidney;
  • Recipient of a kidney with a cold ischemia time < 30 hours;
  • Graft must be functional (producing greater than or equal to 300 ml of urine within 24 hours after transplantation) at time of randomization.

Exclusion Criteria:

  • Donor organ with a cold ischemic time > 30 hours;
  • Patients who produce less than 300 ml of urine in the first 24 hours post-transplantation;
  • Patients who are recipients of multiple organ transplants;
  • Patients who are recipients of ABO incompatible transplants, or T or B cell cross match positive transplant;
  • Patients with current Panel Reactive Antibodies (PRA) level ≥ 50%;
  • Patients with severe hypercholesterolemia (350 mg/dl) or hypertriglyceridemia (500 mg/dl). Patients on lipid lowering treatment with controlled hyperlipidemia are acceptable;
  • HIV positive patients;
  • Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception;
  • Decisional impaired subjects who are not medically or mentally capable of providing consent themselves.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Brazil
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02084446
Other Study ID Numbers  ICMJE CRAD001ABR25T
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Ronaldo de Matos Esmeraldo, MD, Hospital Geral de Fortaleza
Study Sponsor  ICMJE Ronaldo de Matos Esmeraldo, MD
Collaborators  ICMJE Novartis Pharmaceuticals
Investigators  ICMJE
Principal Investigator: Ronaldo M Esmeraldo, MD Hospital Geral de Fortaleza
PRS Account Hospital Geral de Fortaleza
Verification Date February 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP